CDX
NCI-H82
Tumor indication
Lung
Tumor subtype
SCLC
Description
NCI-H82 (Small Cell Lung Cancer CDX Model)
The NCI-H82 line was derived from a patient with small cell lung cancer (SCLC). It exhibits neuroendocrine features typical of this aggressive cancer subtype. NCI-H82 has been a cornerstone in SCLC preclinical research. Its reproducible growth ensures reliability in translational studies.
Key Features:
- Derived from human small cell lung cancer.
- Neuroendocrine phenotype.
- Highly tumorigenic in xenografts.
- Represents aggressive SCLC biology.
Applications:
NCI-H82 is applied in studies of cytotoxic and targeted therapies for SCLC. Researchers use it to investigate neuroendocrine tumor biology. It supports biomarker development and drug resistance studies. Its reproducibility ensures consistent translational outcomes.
Details
- Tumor indication
- Lung
- Tumor subtype
- SCLC
- Organism
- Human
- Mouse sex
- Female
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.